Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
European Medicines Agency, Scientific Discussion of MabCampath (alemtuzumab)
Dimethyl fumarate inhibits integrin α4 expression in multiple sclerosis models.
SigmaPharm Laboratories Products
Oligodendroglial membrane dynamics in relation to myelin biogenesis.
Visualization of myelination in GFP-transgenic zebrafish.
Interferon-beta(1b) treatment in neuromyelitis optica.
Antioxidative enzymes activity and malondialdehyde concentration during mitoxantrone therapy in multiple sclerosis patients.
Information for healthcare professionals: Rituximab
Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.
Gpr126 functions in Schwann cells to control differentiation and myelination via G-protein activation.
Attenuation of 7-ketocholesterol-induced overproduction of reactive oxygen species, apoptosis, and autophagy by dimethyl fumarate on 158N murine oligodendrocytes.
Mitoxantrone repression of astrocyte activation: Relevance to multiple sclerosis.
199 Outcomes after microvascular decompression for patients with trigeminal neuralgia and suspected multiple sclerosis.
The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis.
Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials.
A randomized controlled phase II trial of riluzole in early multiple sclerosis.
Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.
Oral Laquinimod for Multiple Sclerosis Treatment Significantly Reduced Disease Activity and Disability Progression While Providing Good Safety and Tolerability
Primary infection with the Epstein-Barr virus and risk of multiple sclerosis.
Boxed warning of HBV risk added to Rituxan, Arezerra
Gray matter SWI-filtered phase and atrophy are linked to disability in MS .
Glatiramer acetate (GA) prevents TNF-α-induced monocyte adhesion to primary endothelial cells through interfering with the NF-κB pathway.
Oral Tolerance Induction in Experimental Autoimmune Encephalomyelitis with Candida utilis Expressing the Immunogenic MOG35-55 Peptide.
Statement on a nonproprietary name adopted by the USAN Council
Pages
« first
‹ previous
…
54
55
56
57
58
59
60
61
62
…
next ›
last »